Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

World Journal of Clinical Cases Pub Date : 2025-11-26 DOI:10.12998/wjcc.v13.i33.112045

Magdalini-Rigina Fragkouli, Anastasios Makris, Christina Mastori-Kourmpani, Nikos Karpettas, Georgios F Hadjigeorgiou, Constantinos Tsioutis, Theodosios D Filippatos, Aris P Agouridis

{"title":"Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis.","authors":"Magdalini-Rigina Fragkouli, Anastasios Makris, Christina Mastori-Kourmpani, Nikos Karpettas, Georgios F Hadjigeorgiou, Constantinos Tsioutis, Theodosios D Filippatos, Aris P Agouridis","doi":"10.12998/wjcc.v13.i33.112045","DOIUrl":null,"url":null,"abstract":"Background: Psoriasis is a chronic inflammatory condition related to an increased atherosclerotic cardiovascular disease (ASCVD) risk.Aim: To investigate whether lipoprotein (a) [Lp(a)] levels are increased in patients with psoriasis.Methods: A comprehensive literature search up to January 30, 2025 was conducted utilizing PubMed and Cochrane Library databases. A qualitative synthesis and a meta-analysis on Lp(a) mean differences (MD) between psoriasis cases and healthy controls (HC) was performed. The protocol of this meta-analysis has been registered to PROSPERO (No. CRD420250652465).Results: Eighteen studies with 1650 psoriasis patients and 1621 HC were eligible for qualitative synthesis. Pooled analysis from 16 studies (1401 psoriasis patients and 1320 HC) demonstrated that psoriasis patients had significantly higher Lp(a) levels compared with the HC group (MD: 6.72 mg/dL, 95%CI: 4.32-9.12, P < 0.00001, I 2 = 71%). Sensitivity analyses according to the region of origin was also performed. The pooled analysis of the European sub-population showed a pronounced increase in Lp(a) levels in 189 patients with psoriasis vs 178 HC (MD: 15.86 mg/dL, 95%CI: 5.79-25.92, P < 0.002, I 2 = 79%), while the pooled analysis on the Asian sub-population demonstrated a smaller but still significant difference in Lp(a) levels between 1177 psoriasis patients and 1127 HC (MD: 4.95 mg/dL, 95%CI: 2.99-6.92, P < 0.00001, I 2 = 58%).Conclusion: Our findings suggest that Lp(a) levels are significantly elevated in psoriasis patients, further adding to their ASCVD risk.","PeriodicalId":23912,"journal":{"name":"World Journal of Clinical Cases","volume":"13 33","pages":"112045"},"PeriodicalIF":1.0000,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678906/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Clinical Cases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12998/wjcc.v13.i33.112045","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Psoriasis is a chronic inflammatory condition related to an increased atherosclerotic cardiovascular disease (ASCVD) risk.

Aim: To investigate whether lipoprotein (a) [Lp(a)] levels are increased in patients with psoriasis.

Methods: A comprehensive literature search up to January 30, 2025 was conducted utilizing PubMed and Cochrane Library databases. A qualitative synthesis and a meta-analysis on Lp(a) mean differences (MD) between psoriasis cases and healthy controls (HC) was performed. The protocol of this meta-analysis has been registered to PROSPERO (No. CRD420250652465).

Results: Eighteen studies with 1650 psoriasis patients and 1621 HC were eligible for qualitative synthesis. Pooled analysis from 16 studies (1401 psoriasis patients and 1320 HC) demonstrated that psoriasis patients had significantly higher Lp(a) levels compared with the HC group (MD: 6.72 mg/dL, 95%CI: 4.32-9.12, P < 0.00001, I ² = 71%). Sensitivity analyses according to the region of origin was also performed. The pooled analysis of the European sub-population showed a pronounced increase in Lp(a) levels in 189 patients with psoriasis vs 178 HC (MD: 15.86 mg/dL, 95%CI: 5.79-25.92, P < 0.002, I ² = 79%), while the pooled analysis on the Asian sub-population demonstrated a smaller but still significant difference in Lp(a) levels between 1177 psoriasis patients and 1127 HC (MD: 4.95 mg/dL, 95%CI: 2.99-6.92, P < 0.00001, I ² = 58%).

Conclusion: Our findings suggest that Lp(a) levels are significantly elevated in psoriasis patients, further adding to their ASCVD risk.

Abstract Image

查看原文本刊更多论文

牛皮癣患者脂蛋白(a)水平升高：一项最新的系统综述和荟萃分析

背景：银屑病是一种慢性炎症性疾病，与动脉粥样硬化性心血管疾病（ASCVD）风险增加有关。目的：探讨牛皮癣患者脂蛋白(a) [Lp(a)]水平是否升高。方法：利用PubMed和Cochrane图书馆数据库进行截至2025年1月30日的综合文献检索。对银屑病患者与健康对照（HC）的Lp(A)均值差异（MD）进行定性综合和meta分析。本荟萃分析的方案已在普洛斯彼罗（PROSPERO）注册。CRD420250652465)。结果：18项研究1650例牛皮癣患者和1621例HC符合定性综合。16项研究（1401例牛皮癣患者和1320例HC）的汇总分析表明，牛皮癣患者的Lp(a)水平明显高于HC组（MD: 6.72 mg/dL, 95%CI: 4.32 ~ 9.12, P < 0.00001, I 2 = 71%）。根据产地进行了敏感性分析。欧洲亚群的汇总分析显示，189名银屑病患者的Lp(a)水平明显高于178名HC (MD: 15.86 mg/dL, 95%CI: 5.79-25.92, P < 0.002, I 2 = 79%)，而亚洲亚群的汇总分析显示，1177名银屑病患者和1127名HC （MD: 4.95 mg/dL, 95%CI: 2.99-6.92, P < 0.00001, I 2 = 58%）之间Lp(a)水平差异较小，但仍具有显著性。结论：我们的研究结果表明，银屑病患者的Lp(a)水平显著升高，进一步增加了ASCVD的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Clinical Cases Medicine-General Medicine

自引率

0.00%

发文量

3384

期刊介绍： The World Journal of Clinical Cases (WJCC) is a high-quality, peer reviewed, open-access journal. The primary task of WJCC is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of clinical cases. In order to promote productive academic communication, the peer review process for the WJCC is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCC are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in clinical cases.